EVALUATION OF EFFECT OF KETOFOL AND KETODEX IN ELECTROCONVULSIVE THERAPY
Phase 2
Completed
- Conditions
- Health Condition 1: F32- Major depressive disorder, singleepisodeHealth Condition 2: F32- Major depressive disorder, singleepisodeHealth Condition 3: F30-F39- Mood [affective] disorders
- Registration Number
- CTRI/2021/06/034235
- Lead Sponsor
- All India Institute of Medical Sciences New Delhi India
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion Criteria
All ASA 1-3 Patients who are scheduled for ECT treatment for depression
Exclusion Criteria
1. Patients with any serious co-morbidities like cardiovascular disease cerebrovascular disease, intracranial hypertension and Respiratory tract infection.
2. Presence of foreign body like pacemaker clips and intracranial electrode.
3. History of substance abuse or dependence like alcohol
4. ASA 4-5 status
5. History of serious adverse effects related to anaesthesia drugs like allergy.
6. Co-existence of a psychiatric disorder along with major depression.
7. Pregnancy.
8.History of seizures.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the effects of Ketofol and Ketodex on Duration of seizure activity (motor and EEG)Timepoint: within 15 min
- Secondary Outcome Measures
Name Time Method Cortical activity(using fNIRS)Timepoint: within 20 min;Hemodynamic profile( HR ,SBP , DBP ,MAP)Timepoint: within 30 min;Recovery times(Spontaneous breathing, opens eye, obeys command)Timepoint: within 20 min